Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 12/20 | 0.59 |
| ▸ | TP53 | P04637 | 4/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30670771 | 1.00 | LMNA (0.59) | LMNATP53RXFP1POLBTHRB | |
| SCHEMBL26601217 | 0.92 | LMNA (0.65) | LMNATP53POLBTHRBMAPT | |
| SCHEMBL30670707 | 0.92 | LMNA (0.65) | LMNATP53POLBTHRBMAPT | |
| SCHEMBL26601140 | 0.91 | LMNA (0.72) | LMNATP53RXFP1POLBTHRB | |
| SCHEMBL26601181 | 0.90 | LMNA (0.70) | LMNATP53RXFP1POLBTHRB | |
| SCHEMBL26601010 | 0.87 | LMNA (0.71) | LMNATP53RXFP1POLBTHRB | |
| SCHEMBL26601083 | 0.87 | LMNA (0.66) | LMNATP53RXFP1POLBTHRB | |
| SCHEMBL30670750 | 0.87 | LMNA (0.66) | LMNATP53RXFP1POLBTHRB | |
| SCHEMBL26601040 | 0.86 | LMNA (0.76) | LMNATP53RXFP1POLBTHRB | |
| SCHEMBL26600982 | 0.86 | LMNA (0.67) | LMNATP53RXFP1POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2025-09-11 | — | — | US | claimed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | claimed |
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2025-09-11 | — | — | US | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | TFEB, MITF, CREBBP | LMNA 852/4885TP53 1013/4885RXFP1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.